Correlation Between Athira Pharma and PTC Therapeutics

Can any of the company-specific risk be diversified away by investing in both Athira Pharma and PTC Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Athira Pharma and PTC Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Athira Pharma and PTC Therapeutics, you can compare the effects of market volatilities on Athira Pharma and PTC Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Athira Pharma with a short position of PTC Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Athira Pharma and PTC Therapeutics.

Diversification Opportunities for Athira Pharma and PTC Therapeutics

-0.65

Correlation Coefficient

Athira Pharma  PTC Therapeutics

Excellent diversification

The 3 months correlation between Athira and PTC is -0.65. Overlapping area represents the amount of risk that can be diversified away by holding Athira Pharma and PTC Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on PTC Therapeutics and Athira Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Athira Pharma are associated (or correlated) with PTC Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of PTC Therapeutics has no effect on the direction of Athira Pharma i.e., Athira Pharma and PTC Therapeutics go up and down completely randomly.

Pair Corralation between Athira Pharma and PTC Therapeutics

Given the investment horizon of 90 days Athira Pharma is expected to under-perform the PTC Therapeutics. In addition to that, Athira Pharma is 1.76 times more volatile than PTC Therapeutics. It trades about -0.2 of its total potential returns per unit of risk. PTC Therapeutics is currently generating about 0.13 per unit of volatility. If you would invest  4,577  in PTC Therapeutics on December 28, 2024 and sell it today you would earn a total of  922.00  from holding PTC Therapeutics or generate 20.14% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Athira Pharma  vs.  PTC Therapeutics

Athira Pharma

Risk-Adjusted Performance

Very Weak

Over the last 90 days Athira Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

PTC Therapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in PTC Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain fundamental indicators, PTC Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Athira Pharma and PTC Therapeutics

The main advantage of trading using opposite Athira Pharma and PTC Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Athira Pharma position performs unexpectedly, PTC Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PTC Therapeutics will offset losses from the drop in PTC Therapeutics' long position.

The idea behind Athira Pharma and PTC Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.